1) Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. an experimental investigation in several animal species. Acta Radiol Suppl. 1996;408:1-25.
【4.3-01】
2) Mann JD, Wakim KG, Baggenstoss AH. Alterations in the vasculature of the diseased liver.
Gastroenterology. 1953;25:540-6.【4.3-02】
3) Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:
969-85.【4.3-03】
4) Honjo I, Matsumura H. Vascular distribution of hepatic tumors. experimental study. Rev Int Hepatol. 1965;15:681-90.【4.3-04】
5) Nilsson LAV, Zettergren L. Blood supply and vascular pattern of induced primary hepatic carcinoma in rats. a microangiopraphic and histologic investigation. Acta Pathol Microbiol Scand. 1967;71:179-86.【4.3-05】
6) Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer. 1983;52:2193-200.【4.3-06】
7) Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology. 1985;154:15-7.【4.3-07】
8) Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154:19-24.【4.3-08】
9) Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 1984;54:2367-74.【4.3-09】
10) Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, et al. Phase I study of YM 881 (zinostatin stimalamer) suspension by hepatic arterial infusion. Jpn J Cancer Chemother.
1991;18:1657-63.【4.3-10】
11) Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, et al. Phase II study of YM 881 (zinostatin stimalamer) suspension injected into the hepatic artery. Jpn J Cancer Chemother.
1991;18:1665-75.【4.3-11】
12) Maeda H. SMANCS/Lipiodol. Jpn J Cancer Chemother. 1994;21:907-13.【4.3-12】
13) Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE.
Epirubicin-lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer. 1995;76:2202-10.【4.3-13】
14) Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y, Cooperative study group for liver cancer treatment in shikoku area. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33:S93-6.【4.3-14】
15) Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial
injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer. 1989;64:1586-94.【4.3-15】
16) Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma.
Hepatology. 2002;35:1164-71.【4.3-16】
17) 日本肝癌研究会追跡調査委員会. 第16回全国原発性肝癌追跡調査報告.【4.3-17】 18) 坂口 達哉, 吉松 俊治, 相良 勝郎, 山下 康行, 高橋 睦正. 肝細胞癌に対する
SMANCS 動注療法における肝動脈閉塞についての検討. 日本医放会誌. 1998;58:
700-4.【4.3-18】
19) Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, et al. Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma.
J Gastroenterol. 2000;35:353-60.【4.3-19】
20) Okusaka T, Okada S, Ueno H, Ikeda M. Iwata R, Furukawa H, et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 2002;62:
228-33.【4.3-20】
21) 日本臨床腫瘍研究会 編. 臨床腫瘍学. 第 2 版. 東京: 癌と化学療法社; 1999. p.
595-612.【4.3-21】
22) Fukushima S, Kishimoto S, Hayashi Y, Kaneko M, Nakano M. Intra-hepatic artery infusional chemotherapy with cisplatin suspension in Lipiodol (LPS) for hepatocellular carcinoma (I). J Jpn Soc Cancer Ther. 1988;23:2743-9.【4.3-22】
23) 松久 哲章, 森岡 三紀子, 相原 陽子, 三好 京子, 成瀬 利麻子, 坂本 聡, ほか.
Cisplatin注射液からの原末精製とLipiodol懸濁液の調製-肝細胞癌に対する動注化学 療法の一環として-. 医薬ジャーナル. 1991;27:2715-21.【4.3-23】
24) Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 2001;59:657-63.【4.3-24】
25) Melvik JE, Pettersen EO. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by methionine. Inorganica Chim Acta. 1987;137:115-8.【4.3-25】
26) Maeda M, Uchida NA, Sasaki T. Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77:523-5.【4.3-26】
27) Luo FR, Yen T-Y, Wyrick SD, Chaney SG. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B. 1999;724:
345-56.【4.3-27】
28) Luo FR, Wyrick SD, Chaney SG. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol. 1999;44:19-28.【4.3-28】
29) Luo FR, Wyrick SD, Chaney SG. Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol. 1999;13:159-69.【4.3-29】
30) Allain P, Heudi O, Cailleux A, Bouil AL, Larra F, Boisdron-Celle M, et al. Early
biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Drug Metab Dispos. 2000;28:1379-84.【4.3-30】
31) Gibbons GR, Wyrick S, Chaney SG. Rapid reduction of tetrachloro (D,L-trans) 1,2-diaminocyclohexaneplatinum (IV) (Tetraplatin) in RPMI 1640 tissue culture medium.
Cancer Res. 1989;49:1402-7.【4.3-31】
32) Chaney SG, Wyrick S, Till GK. In vitro biotransformations of tetrachloro (d,l-trans)- 1,2-diaminocyclohexaneplatinum (IV) (Tetraplatin) in rat plasma. Cancer Res. 1990;50:
4539-45.【4.3-32】
33) Carfagna PF, Wyrick SD, Holbrook DJ, Chaney SG. Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro (d,l-trans)-1,2-diaminocyclohexaneplatinum (IV) (Tetraplatin) in Fischer 344 rats. J Biochem Toxicol. 1991;6:71-80.【4.3-33】
34) Mauldin SK, Gibbons G, Wyrick SD, Chaney SG. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
Cancer Res. 1988;48:5136-44.【4.3-34】
35) Mauldin SK, Plescia M, Richard FA, Wyrick SD, Voyksner RD, Chaney SG. Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane) malonatoplatium (II) by physiologically important compounds in vitro. Biochem Pharmacol. 1988;37:
3321-33.【4.3-35】
36) Maclean DS, Khokhar AR, Tyle P, Perez-Soler R. Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R, R-1, 2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumor agent. J Microencapsul. 2000;17:307-22.【4.3-36】
37) Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000;23:344-8.【4.3-37】
38) 日本化薬株式会社, ブリストル製薬有限会社. DDP-H概要, ヘ．吸収、分布、代謝、
排泄. 医薬品医療機器情報提供ホームページ; 新薬の承認審査に関する情報; 平成 16年1月承認分（http://www.info.pmda.go.jp/shinyaku/g0401.html）. 販売名：動注用 アイエーコール100mg, 動注用コナブリ100mg（一般名：シスプラチン）.
39) 伊藤 隆太, 高橋 良, 本田 西男 編. 新薬開発のための動物モデル利用集成. 東京: R&Dプランニング社; 1985. p. 280-3.【4.3-38】
40) Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res. 2001;478:1-21.【4.3-39】
41) Wong NL, Quamme GA, Dirks JH. Effects of urea on electrolyte transport in the dog kidney.
J Lab Clin Med. 1981;98:741-50.【4.3-40】
42) 杉山 雄一 編. 医薬品開発における薬物動態研究. 東京: 薬業時報社; 1998. p. 119.
【4.3-41】
43) Wolff J. Physiology and pharmacology of iodized oil in goiter prophylaxis. Medicine 2001;